POLYSAN Scientific & Technological Pharmaceutical Company clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-20
What changed in the last 30 days
3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.
- Notable: Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old Primary completion pushed from Jun 2026 to Jun 2027
- Notable: Efficiency of Cytoflavin, · Ischemic Stroke Not Receiving Reperfusion Therapy Primary completion pushed from Sep 30, 2025 to Jun 1, 2027
- Minor: Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation · Post Intensive Care Syndrome Trial completed
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-19 | NCT07949682 Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock | Not Yet Recruiting |
Active trials by phase
| Phase 2/3 | 1 |
Not charted: 3 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when POLYSAN Scientific & Technological Pharmaceutical Company's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.